Announced Mon, 7 Sept, 2026 · 11:24 IST
Novartis India acquires Minipress trademarks from Pfizer for Rs 1,250 cr
NOVARTIND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+11.7%1-day move
₹1642.00
prior close
₹1660.00
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+1.5+1.9+1.3+1.0+11.7+33.2+47.4+44.1+33.4+27.6+17.7+22.4——
Up moveDown movePending
AI summary
Novartis India board approved acquisition of trademarks Minipress and Minipres and related IP from Pfizer Inc USA and Pfizer Products Inc USA for Rs 1,250 crore. Asset purchase agreement signed on Sept 7, 2026 with simultaneous closing. Minipress XL (prazosin), used for hypertension and BPH, recorded Rs 228.6 cr revenue with 6.3% CAGR over 4 years. Not a related party deal.
Likely market impact
Strengthens Novartis India pharma portfolio with an established hypertension brand. Significant Rs 1,250 cr cash outflow for IP acquisition.